Approval · Notice of Compliance 12613 · 2011
MAR-RISPERIDONE: Notice of Compliance 12613
Issued September 7, 2011
A Notice of Compliance is Health Canada’s approval of a drug submission: a new drug, a new use or form, or a change to an approved one. The product itself is in the Drug Product Database, with its current status.
- Notice number
- 12613
- Date
- September 7, 2011
- Company
- Marcan Pharmaceuticals Inc.Ottawa, Ontario, Canada
- Product type
- Prescription Pharmaceutical
- Submission
- Abbreviated New Drug Submission (ANDS)
- Submission class
- Admin
- Reason
- New Manufacturer and Product Name
- Therapeutic class
- Antipsychotic Agent
- Canadian reference product
- RISPERDAL (Janssen-Ortho Inc.)
Products in this notice
| Brand | DIN | Status today |
|---|---|---|
| MAR-RISPERIDONE | 02371766 | Marketed |
| MAR-RISPERIDONE | 02371774 | Marketed |
| MAR-RISPERIDONE | 02371782 | Marketed |
| MAR-RISPERIDONE | 02371790 | Marketed |
| MAR-RISPERIDONE | 02371804 | Marketed |
| MAR-RISPERIDONE | 02371812 | Marketed |
Medicinal ingredients
- RISPERIDONE 0.25 MG per TAB
- RISPERIDONE 0.5 MG per TAB
- RISPERIDONE 1 MG per TAB
- RISPERIDONE 2 MG per TAB
- RISPERIDONE 3 MG per TAB
- RISPERIDONE 4 MG per TAB